Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Bodycote reiterates FY guidance despite YTD revenue decline

(Sharecast News) - Heat treatments and thermal processing services outfit Bodycote reiterated its full-year outlook on Tuesday despite reporting a year-on-year revenue decline for the four months ended 30 April. Bodycote said core revenues were down 5% year-on-year on an organic basis, while overall group revenues were 6% lower at £246.0m, reflecting a 1% headwind from lower energy surcharges year-on-year and a strong prior year comparator.

However, Bodycote also stated it had delivered a sequential run-rate improvement of 4% versus H224, with almost all end markets seeing sequential improvement.

The FTSE 250-listed group said supply chain conditions had improved in the civil aerospace sector during the first four months of FY25, with a "notable acceleration" in March and April. Defence revenue also saw continued growth, led by Western Europe.

Bodycote did note that conditions "remain challenging" in automotive and industrial markets, though also said it has seen "a sequential improvement in activity levels".

When discussing Donald Trump's "Liberation Day" tariffs, Bodycote said it was "closely monitoring" ongoing global trade discussions and announcements but noted that its diversified, local-for-local plant footprint meant that it had "no material direct exposure to cross-border tariffs".

"Our outlook for the full year is in line with current market expectations. Adjusted operating profit in 2025 is expected to be second-half weighted. This reflects the progressive delivery of Optimise benefits through the year, as well as improved performance in specialist technologies supported by new contracts we have won in defence and oil & gas, and further growth in aerospace & defence," said Bodycote.

"Reflecting the uncertain macro-economic environment, our focus is on operational delivery and maintaining strict control of our cost base. We are progressing at pace with our optimise, perform & grow initiatives which will enhance the quality of the business and ensure we are well positioned for the future."

As of 0855 BST, Bodycote shares were up 3.13% at 543.0p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.